NantHealth is a transformational healthcare company converging science and technology through an integrated clinical platform that’s empowering physicians, patients, payers, and researchers to transcend the traditional barriers of today’s healthcare system. The Company's solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical delivery with clinical data and promoting wellness for a healthier.
Type
Public
HQ
Culver City, US
Founded
2007
Size (employees)
922 (est)
NantHealth was founded in 2007 and is headquartered in Culver City, US
Report incorrect company information

Key People/Management at NantHealth

Patrick Soon-Shiong

Patrick Soon-Shiong

CEO and Chairman of the Board
Paul A. Holt

Paul A. Holt

CFO
Ron Louks

Ron Louks

COO

NantHealth Office Locations

NantHealth has offices in Culver City and London
Culver City, US (HQ)
9920 Jefferson Blvd
London, GB
Warnford Court, 29 Throgmorten Street
Show all (2)
Report incorrect company information

NantHealth Financials and Metrics

NantHealth Financials

NantHealth's revenue was reported to be $100.38 m in FY, 2016 which is a 72.2% increase from the previous period.
USD

Revenue (Q3, 2017)

21.8 m

Gross profit (Q3, 2017)

10.3 m

Gross profit margin (Q3, 2017), %

47.3%

Net income (Q3, 2017)

(42.4 m)

EBIT (Q3, 2017)

(16 m)

Market capitalization (20-Apr-2018)

386.4 m

Cash (30-Sep-2017)

73.5 m
NantHealth's current market capitalization is $386.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

33.9 m58.3 m100.4 m

Revenue growth, %

72%72%

Cost of goods sold

24.2 m34.8 m72.3 m

Gross profit

9.7 m23.5 m28 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

19.5 m31.5 m25.4 m22.5 m26.2 m21.8 m

Cost of goods sold

13 m22.2 m17.2 m19 m16.7 m11.5 m

Gross profit

6.4 m9.3 m8.1 m3.5 m9.6 m10.3 m

Gross profit Margin, %

33%29%32%15%36%47%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

3.7 m6 m160.4 m

Accounts Receivable

2.4 m11.5 m13.7 m

Prepaid Expenses

1.6 m8.7 m5 m

Inventories

2.9 m2.1 m2.2 m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

95.2 m75.8 m124.9 m92.7 m73.5 m

Accounts Receivable

17.2 m12.9 m8.9 m11.3 m12 m

Prepaid Expenses

8.7 m5.8 m5.8 m5.2 m4.2 m

Inventories

2.3 m1.8 m2.2 m2.2 m974 k
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(84.6 m)(72 m)(184.1 m)

Depreciation and Amortization

16.2 m(15.8 m)(30.9 m)

Inventories

(2.3 m)982 k(570 k)

Accounts Payable

1.6 m1.7 m(5.6 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(33.1 m)87.3 m(124.2 m)(41.1 m)(111.2 m)(153.6 m)

Depreciation and Amortization

7.8 m15.5 m23 m8.3 m16.4 m23.3 m

Inventories

(51 k)(196 k)(135 k)42 k6 k61 k

Accounts Payable

(5.7 m)(4.8 m)(4.3 m)(2.4 m)(4 m)(966 k)
USDY, 2017

Financial Leverage

2.2 x
Show all financial metrics

NantHealth Operating Metrics

Q2, 2016Q3, 2016FY, 2016Q1, 2017May, 2017Q2, 2017Q3, 2017

Covered Lives

100 m100 m

Customer Transactions

30 m

Patents (US)

5 6 6 6 6 3

Patents (foreign)

1 1 1 1 1
Show all operating metrics

NantHealth Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
NantHealth Singapore Pte Ltd
Net. Orange, Ltd
NaviNet, Inc.
NaviNet Limited
AZ Home Health, LLC
NantHealth Ltd
Nant Health Canada, Inc.
Assisteo Holding, Inc.
NantHealth Technologies India Private Ltd
Report incorrect company information

NantHealth News and Updates

Cher sues NantHealth's Soon-Shiong again, asks for jury trial

The iconic entertainer claims the biotech mogul lied to the LA Times about knowing she was a stakeholder in Altor Biosciences.

Cher sues NantHealth's Patrick Soon-Shiong alleging stock sale fraud

The legendary singer claims Soon-Shiong and other Altor board members hid the success of a promising cancer and AIDS/HIV drug.

Altor investors amend suit against Patrick Soon-Shiong, claim mogul paid off board members

Altor Bioscience stakeholders say the NantHealth CEO low-balled the company’s value and paid off two directors in an attempt to buy the company through a sweetheart deal.

Patrick Soon-Shiong sued over capital investment in biotech firm

A Precision Biologics stockholder is accusing the NantHealth founder and controlling board members of breaching contract and fiduciary duty.
Show more
Report incorrect company information